Citations

Clear

3 citation(s) found for "Song, James".

Clinical Utility of a Digital Dermoscopy Image-Based Artificial Intelligence Device in the Diagnosis and Management of Skin Cancer by Dermatologists
Witkowski, Alexander , Burshtein, Joshua , Cockerell, Clay J. , Correa‐Selm, Lilia , Cotter, David G. , Ellis, Darrell L., Farberg, Aaron S. , Grant-Kels, Jane M, Greiling, Teri M. , Grichnik, James M. , Leachman, Sancy A. , Linfante, Anthony , Marghoob, Ashfaq A. , Paragh, György , Rabinovitz, Harold , Rigel, Darrell S. , Siegel, Daniel M. , Song, Eingun James , Swanson, David C. , Trask, David, Łudzik, Joanna , Correa, Lilia , Greiling, Teri M , Grichnik, James M , Leachman, Sancy A , Paragh, Gyorgy , Siegel, Daniel M , Song, Eingun James , Swanson, David, Ludzik, Joanna , Christopher, Michael, Ellis, Darrell L., Grant-Kels, Jane Margaret , Marks, Etan , Nguyen, Khoa, Ortega‐Loayza, Alex G. , Pellacani, Giovanni , Trask, David

Mayo Clinic

Cancers | October 25, 2024 | Volume: 16 | Issue: 21 | Pages: 3592

10.3390/cancers16213592 | PMID 39518033 Get It

Background: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. Objective: To evaluate the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm (DDI-AI device) on the diagnosis and management of skin cancers by dermatologists. Methods: Thirty-six United States board-certified dermatologists evaluated 50 clinical images and 50 digital dermoscopy images of the same skin lesions (25 malignant and 25 benign), first without and then with knowledge of the DDI-AI device output. Participants indicated whether they thought the lesion was likely benign (unremarkable) or malignant (suspicious). Results: The management sensitivity of dermatologists using the DDI-AI device was 91.1%, compared to 84.3% with DDI, and 70.0% with clinical images. The management specificity was 71.0%, compared to 68.4% and 64.9%, respectively. The diagnostic sensitivity of dermatologists using the DDI-AI device was 86.1%, compared to 78.8% with DDI, and 63.4% with clinical images. Diagnostic specificity using the DDI-AI device increased to 80.7%, compared to 75.9% and 73.6%, respectively. Conclusion: The use of the DDI-AI device may quickly, safely, and effectively improve dermoscopy performance, skin cancer diagnosis, and management when used by dermatologists, independent of training and experience.
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
Uronis, Hope E. , Sirard, Cynthia A. , Kagey, Michael H. , Baum, Jason , Song, James, Wang, Jin , Kim, In-Ho , Lee, Keun Wook, Oh, Do‐Youn , Sonbol, Bassam Bassam, Klempner, Samuel J. , Chao, Joseph , Wainberg, Zev A. , Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 292-292

10.1200/jco.2022.40.4_suppl.292 Get It

292 Background: Despite recent approval of anti-PD-1 antibodies as 1L therapy in HER2(-) advanced GEA, benefit remains modest and limited largely to PD-L1(+) patients (pts), primarily those with combined positive scores (CPS) ≥5. Thus novel therapeutic approaches are needed for this pt population. DKN-01 is a targeted anti-DKK1 mAb which has demonstrated improved clinical outcomes in pts with elevated tumoral DKK1 expression, a subset of pts with more aggressive disease and shorter overall survival. Methods: DisTinGuish (NCT04363801) is a Phase 2a single arm 2-part trial; Part A investigated DKN-01 (D) + tislelizumab (TS) + CAPOX as 1L therapy for pts with advanced HER2(-) GEA regardless of DKK1 status; Part B investigated two dosing cohorts of D (300 mg and 600 mg) + TS as 2L therapy for DKK1-high advanced GEA pts. Primary objective was to examine safety and tolerability and secondary objectives evaluated multiple efficacy endpoints including overall response rate (ORR) in a modified intent to treat (mITT) population (>1 dose D). Results: Forty-nine pts enrolled between 01 Sept 2020 and 15 Sept 2021; 25 pts in Part A and 24 pts in Part B (D-300 mg). Key clinicopathologic features and efficacy outcomes are shown in Table. The most common D-related AEs were low grade (G1/2) fatigue, nausea, and diarrhea. Nine pts had D-related ≥G3 toxicities, elevated AST/ALT, elevated alkaline phosphatase, hypophosphatemia, hyponatremia, lymphopenia, neutropenia, diarrhea, vomiting, fatigue all occurring in 1 pt and pulmonary embolism in 2 pts (one G5 event). No new safety signals were observed in Part A or B1. Duration of response (DoR), median PFS and median OS have not been reached for Part A. Last pt enrolled in Part B1 on 15 Sept 2021. Conclusions: The combination of D/TS + CAPOX represents a well-tolerated, active 1L combination, particularly for DKK1-high patients consistent with the proposed mechanism of action. Activity appears to be independent of PD-L1 status. Part B1 is aligned with biomarker enrichment and efficacy and biomarker data will be presented along with updated Part A efficacy data. Clinical trial information: NCT04363801. [Table: see text]
Hydrogen Peroxide-Generating Electrochemical Scaffold Activity against Trispecies Biofilms
Raval, Yash S. , Mohamed, Abdelrhman , Song, James , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Patel, Robin , Mohamed, A , Beyenal, Haluk , Raval, Yash S.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 17, 2020 | Volume: 64 | Issue: 4 | Pages: No page available

10.1128/aac.02332-19 | PMID 31964793 Get It

The antibiofilm activity of a hydrogen peroxide-generating electrochemical scaffold (e-scaffold) was determined against mono- and trispecies biofilms of methicillin-resistant Staphylococcus aureus , multidrug-resistant Pseudomonas aeruginosa , and Candida albicans . Significant time-dependent decreases were found in the overall CFU of biofilms of all three monospecies and the trispecies forms. Confocal laser scanning microscopy showed dramatic reductions in fluorescence intensities of biofilm matrix protein and polysaccharide components of e-scaffold-treated biofilms.